Two bispecific antibodies have already been approved, Catumaxomab and Blinatumomab, targeting EpCAM and CD3 and CD19 and CD3 in malignant ascites and acute lymphoblastic leukemia, respectively (Suurs et al., 2019). This evidence concerns the gene EPCAM and acute lymphoblastic leukemia.